The 180-Day Exclusivity Trap: Why First to File Winners Still Lose Money
In pharma, first to file sounds like a shortcut to profit. And in Hatch-Waxman, it often isat least on paper.
But a growing body of disputes and outcomes suggest a harsher truth: …

Most pharma wins arent won in court. Theyre won in the math.
Heres the hard truth: drug patent settlements are often treated like a default strategya clean, predictable way to buy time, avoid litigation costs, and move on.
But default can become expens…

Patents dont fail all at once. They crack where the defenses are thin.
Think of a drug patent portfolio like a fortress. You may have thick wallscore claims tied to a particular method of use, formulation, or device-mediated therapeutic step. But in th…

The Salt Change Trap: When a New Patent Buys You Nothing
Theres a quiet regulatory maneuver happening across Big Pharmaand it rarely makes headlines.
A salt change can look like a technical footnote in an otherwise familiar drug story: same active ingr…

Pediatric exclusivity is often sold as a public-health win: six extra months of market protection in exchange for pediatric studies. But that framing misses the real-world mathespecially for companies building pipelines, patients waiting for therapies,…

Bausch Healths patent fight isnt just a courtroom headlineits a live test of how fast generic challengers can translate design-around into market reality.
In the U.S. pharmaceutical ecosystem, litigation is often framed as a delay tactic. But in case…

Exelixis v. Intas isnt just another pharma patent skirmishits a live case study in how drug innovation survives (or doesnt) after the first blockbuster wave.
Heres the hook: when the legal clock starts running, the real battlefield isnt only in court f…

🚨 A $ and a precedent are on the line in Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. (DrugPatentWatch blog)
If youve been watching the quiet chess match between brand and generic drug makers, this case deserves your attentionbecause …

Exelixis vs. Handa: The Patent Fight That Signals How Biotechs Second Wave Deals Will Be Won
Biotech patent battles rarely feel like pure courtroom dramas. Theyre more like chess matches played on a clockwhere a single ruling can decide who gets to sel…

Takeda just scored a win in a fight that matters far beyond the courtroom.
In a decision covered in DrugPatentWatch, Takeda Pharmaceuticals U.S.A., Inc. v. Sun Pharmaceutical Industries Ltd. highlights a reality that brand and generic players both know…